News stories about Cytosorbents Corporation (NASDAQ:CTSO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytosorbents Corporation earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 45.8112208107065 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Cytosorbents Corporation (CTSO) remained flat at $6.15 during midday trading on Tuesday. 45,868 shares of the company’s stock were exchanged. The firm’s market cap is $173.02 million. Cytosorbents Corporation has a 1-year low of $3.30 and a 1-year high of $6.70. The stock has a 50-day moving average price of $5.93 and a 200 day moving average price of $4.97.
Cytosorbents Corporation (NASDAQ:CTSO) last announced its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. On average, analysts predict that Cytosorbents Corporation will post ($0.27) EPS for the current fiscal year.
CTSO has been the topic of several research analyst reports. Maxim Group set a $10.00 price objective on Cytosorbents Corporation and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine upgraded Cytosorbents Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. B. Riley restated a “buy” rating and set a $11.25 price objective on shares of Cytosorbents Corporation in a research note on Wednesday, August 2nd. HC Wainwright set a $13.00 price objective on Cytosorbents Corporation and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Finally, Aegis restated a “buy” rating and set a $9.00 price objective on shares of Cytosorbents Corporation in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $10.45.
COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/10/31/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cytosorbents-corporation-ctso-stock-price.html.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
What are top analysts saying about Cytosorbents Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytosorbents Corporation and related companies.